{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'Circumstances that may warrant termination or suspension include, but are not limited to:', 'Determination of unexpected, significant, or unacceptable risk to participants', 'Demonstration of efficacy that would warrant stopping', 'Insufficient compliance to protocol requirements', 'Data that are not sufficiently complete and/or evaluable', 'Determination that the primary endpoint has been met', 'Determination of futility', 'Study may resume once concerns about safety, protocol compliance, and data quality are addressed, and satisfy the', 'NIAMS, IRBs, and/or FDA.', '11.1.3 CONFIDENTIALITY AND PRIVACY', 'Participant confidentiality and privacy will be strictly held in trust by the participating investigators, their staff, and their', 'interventions. This confidentiality is extended to cover testing of biological samples in addition to the clinical information', 'relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be', 'held in strict confidence. All research activities will be conducted in as private a setting as possible.', 'The study monitor, other authorized representatives of the NIAMS, representatives of the IRB, regulatory agencies or', 'pharmaceutical company supplying study product may inspect all documents and records required to be maintained by', 'the investigators, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the', 'participants in this study. The clinical study site will permit access to such records.', \"The study participant's contact information will be securely stored at each clinical site for internal use during the study.\", 'At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by the', 'reviewing IRB, Institutional policies, or NIAMS requirements.', 'Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted', 'to and stored at the (DCC, based in the UAB Department of Biostatistics in the School of Public Health, directed by Dr.', \"Gary Cutter (Co-Investigator). This will not include the participant's contact or identifying information. Rather, individual\", 'participants and their research data will be identified by a unique study identification number. The study data entry and', 'study management systems used by clinical sites and by research staff will be secured and password protected. At the', 'end of the study, all study databases will be archived at UAB.', '11.1.4 FUTURE USE OF STORED SPECIMENS AND DATA', \"With the participant's approval and as approved by local Institutional Review Boards (IRBs), de-identified biological\", 'samples will be stored at the lab of John Mountz, MD, PhD at the University of Alabama at Birmingham. These samples', 'could be used to for further research into the effects of MMF on pegloticase immunogenicity, its complications and', 'other conditions for which individuals with gout are at increased risk, and to improve treatment. The Bridges Lab will', 'also be provided with a code-link that will allow linking the biological specimens with the phenotypic data from each', 'participant, maintaining the blinding of the identity of the participant.', 'During the conduct of the study, an individual participant can choose to withdraw consent to have biological specimens', 'stored for future research. When the study is completed, access to study data and/or samples will be reviewed and', 'approved by the Coordinating Center at UAB, and provided through the Bridges Lab.', '37']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', '11.1.5 KEY ROLES AND STUDY GOVERNANCE', 'Principal Investigator', 'Medical Monitor', 'Kenneth G. Saag, MD, MSc', 'Benjamin P. Butitta, MBA, CCRP', 'University of Alabama at', 'University of Alabama at', 'Birmingham', 'Birmingham', 'FOT 820, Birmingham AL 35294', 'Ryals School of Public Health', '205-996-9784', '225-603-5738', 'ksaag@uabmc.edu', 'bbutitta@uab.edu', '11.1.6 SAFETY OVERSIGHT', 'In collaboration with NIAMS and KAI, we will convene a DSMB for additional monitoring of study procedures. The safety', 'of the study participants is the highest priority for this project. The ability to make appropriate, sound scientific decisions', 'regarding the outcome of each participant as early as possible is the top priority and as such, a process for the ongoing', 'monitoring of results by independent scientists is important to maintain throughout the duration of the project. The', 'DSMB will be comprised of 3 scientists who are independent of the study, the study investigators, and the University of', 'Alabama at Birmingham and the University of Michigan for this clinical trial.', '11.1.7 CLINICAL MONITORING', 'Benjamin Butitta, MBA, CCRP, a member of the DCC at UAB, will conduct clinical site monitoring. Clinical monitoring will', 'be conducted to ensure that the rights and well-being of trial participants are protected, that the reported trial data are', 'accurate, complete, and verifiable, and that the conduct of the trial is in compliance with the currently approved', 'protocol/amendment(s), with International Conference on Harmonization Good Clinical Practice (ICH GCP), and with', 'applicable regulatory requirement(s).', 'Sites will be monitored within at least 4-6 weeks of enrolling their second participant. Subsequent visits will take place', 'every 6 months, or in the event there is an identified need for a visit. Independent audits will be conducted by the DCC', 'to ensure monitoring practices are performed consistently across all participating sites and that monitors are following', 'the CMP.', 'Case report forms and de-identified study source documents (including informed consent) for the first participant at', 'each site will be submitted to the via email at recipe@uabmc.edu for review within 2 weeks of the baseline exam.', 'Source documents will include: medical history, clinical notes, lab reports, informed consent process documentation,', 'research lab worksheets, etc. Source documents will be checked against the eDES case report forms and the case report', 'forms will be checked against the database tables. Printed laboratory reports and reports from the electronic medical', 'record must include the date printed and signed by staff member printing the report. This will permit remote monitoring', 'in a timely manner and can identify errors early in the data acquisition and entry process.', '1.', 'Monitoring visits will be conducted using the following guidelines:', 'a. Sites will be notified at least 30 days prior to the site visit.', 'b. 100% regulatory review, including informed consent review, will be conducted using a combination of files and', 'onsite review.', 'C.', 'Ideally, at least one study participant record per activated clinical trial will be reviewed per site during a single', 'visit', \"The data of a site's first enrollment will be 100% reviewed by the monitor.\", 'At least one study participant case review will be conducted, with no upper limit; more cases can be added', 'at the discretion of the DCC and monitor.', 'd.', 'The monitor will provide a preliminary report at the close of the monitoring visit.', '38']\n\n###\n\n", "completion": "END"}